Dan Siskind1,2, Erin Gallagher1,2, Karl Winckel3,4, Samantha Hollingworth3, Steve Kisely1,2,5, Joseph Firth6, Christoph U Correll7,8,9, Wade Marteene10. 1. Metro South Addiction and Mental Health Service, Brisbane, Australia. 2. School of Medicine, University of Queensland, Brisbane, Australia. 3. School of Pharmacy, University of Queensland, Brisbane, Australia. 4. Department of Pharmacy, Princess Alexandra Hospital, Brisbane, Australia. 5. Department of Psychiatry, Community Health and Epidemiology, Dalhousie University, Halifax, Canada. 6. Division of Psychology and Mental Health, University of Manchester, Manchester, UK. 7. Department of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY. 8. Department of Psychiatry, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, NY. 9. Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany. 10. Department of Pharmacy, Redlands Hospital, Cleveland, QLD, Australia.
Abstract
OBJECTIVE: Obesity and adverse metabolic outcomes in patients with severe mental illness are clinically significant but potentially preventable. Importantly, the evidence for switching to antipsychotics to reduce cardiometabolic burden is unclear. METHOD: PubMED, Embase, PsycINFO, and Cochrane were searched from inception to March 8, 2020. Articles reporting weight and metabolic changes after antipsychotic switching vs staying on the previous antipsychotic were meta-analyzed both across and within group. RESULTS: Of 61 identified studies, 59 were meta-analyzed (40% rated high quality). In the switch-vs-stay pairwise meta-analyses, only aripiprazole significantly reduced weight (-5.52 kg, 95% CI -10.63, -0.42, P = .03), while olanzapine significantly increased weight (2.46 kg, 95% CI 0.34, 4.57, P = .02). Switching to aripiprazole also significantly improved fasting glucose (-3.99 mg/dl, 95% CI -7.34, -0.64, P = .02) and triglycerides (-31.03 mg/dl, 95% CI -48.73, -13.34, P = .0001). Dropout and psychosis ratings did not differ between switch and stay groups for aripiprazole and olanzapine. In before-to-after switch meta-analyses, aripiprazole (-1.96 kg, 95% CI -3.07, -0.85, P < .001) and ziprasidone (-2.22 kg, 95% CI -3.84, -0.60, P = .007) were associated with weight loss, whereas olanzapine (2.71 kg, 95% CI 1.87, 3.55, P < .001), and clozapine (2.80 kg, 95% CI 0.26, 5.34, P = .03) were associated with weight gain. No significant weight or other cardiometabolic changes were observed when switching to amisulpride, paliperidone/risperidone, quetiapine, or lurasidone. CONCLUSIONS: Switching antipsychotics to agents with lower weight gain potential, notably to aripiprazole and ziprasidone, can improve weight profile and other cardiometabolic outcomes. When choosing switch agents, both the weight gain potential of the pre- and post-switch antipsychotic must be considered. Antipsychotic switching in psychiatrically stable patients must be weighed against the risk of psychiatric worsening.
OBJECTIVE: Obesity and adverse metabolic outcomes in patients with severe mental illness are clinically significant but potentially preventable. Importantly, the evidence for switching to antipsychotics to reduce cardiometabolic burden is unclear. METHOD: PubMED, Embase, PsycINFO, and Cochrane were searched from inception to March 8, 2020. Articles reporting weight and metabolic changes after antipsychotic switching vs staying on the previous antipsychotic were meta-analyzed both across and within group. RESULTS: Of 61 identified studies, 59 were meta-analyzed (40% rated high quality). In the switch-vs-stay pairwise meta-analyses, only aripiprazole significantly reduced weight (-5.52 kg, 95% CI -10.63, -0.42, P = .03), while olanzapine significantly increased weight (2.46 kg, 95% CI 0.34, 4.57, P = .02). Switching to aripiprazole also significantly improved fasting glucose (-3.99 mg/dl, 95% CI -7.34, -0.64, P = .02) and triglycerides (-31.03 mg/dl, 95% CI -48.73, -13.34, P = .0001). Dropout and psychosis ratings did not differ between switch and stay groups for aripiprazole and olanzapine. In before-to-after switch meta-analyses, aripiprazole (-1.96 kg, 95% CI -3.07, -0.85, P < .001) and ziprasidone (-2.22 kg, 95% CI -3.84, -0.60, P = .007) were associated with weight loss, whereas olanzapine (2.71 kg, 95% CI 1.87, 3.55, P < .001), and clozapine (2.80 kg, 95% CI 0.26, 5.34, P = .03) were associated with weight gain. No significant weight or other cardiometabolic changes were observed when switching to amisulpride, paliperidone/risperidone, quetiapine, or lurasidone. CONCLUSIONS: Switching antipsychotics to agents with lower weight gain potential, notably to aripiprazole and ziprasidone, can improve weight profile and other cardiometabolic outcomes. When choosing switch agents, both the weight gain potential of the pre- and post-switch antipsychotic must be considered. Antipsychotic switching in psychiatrically stable patients must be weighed against the risk of psychiatric worsening.
Authors: Joseph P McEvoy; Leslie Citrome; David Hernandez; Josephine Cucchiaro; Jay Hsu; Andrei Pikalov; Antony Loebel Journal: J Clin Psychiatry Date: 2013-02 Impact factor: 4.384
Authors: Eun Young Kim; Sung Man Chang; Joo Cheol Shim; Eun Jeong Joo; Jae Jin Kim; Yong Sik Kim; Yong Min Ahn Journal: Curr Med Res Opin Date: 2013-07-16 Impact factor: 2.580
Authors: T De Marinis; P T Saleem; P Glue; W J Arnoldussen; R Teijeiro; A Lex; M A Latif; R Medori Journal: Pharmacopsychiatry Date: 2007-11 Impact factor: 5.788
Authors: Peter J Weiden; John W Newcomer; Antony D Loebel; Ruoyong Yang; Harold E Lebovitz Journal: Neuropsychopharmacology Date: 2007-07-18 Impact factor: 7.853
Authors: Renato de Filippis; Raffaele Gaetano; Georgios Schoretsanitis; Giuseppe Verde; Cesare Anthony Oliveti; John M Kane; Cristina Segura-Garcia; Pasquale De Fazio Journal: Neuropsychiatr Dis Treat Date: 2021-07-01 Impact factor: 2.570